Status:
COMPLETED
Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents
Lead Sponsor:
Fondation Ophtalmologique Adolphe de Rothschild
Conditions:
Age Related Macular Degeneration
Diabetic Macular Edema
Eligibility:
All Genders
18+ years
Brief Summary
In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitr...
Eligibility Criteria
Inclusion
- Ocular pathology requiring repeated IVT treatment of anti-angiogenic drugs (exudative AMD, diabetic macular edema or secondary to retinal venous occlusion ...)
- Beginning of IVT treatment repeated before 10/01/2019 (6 months before the start of French confinement)
Exclusion
- Refusal to participate
Key Trial Info
Start Date :
May 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 15 2022
Estimated Enrollment :
233 Patients enrolled
Trial Details
Trial ID
NCT04395859
Start Date
May 27 2020
End Date
February 15 2022
Last Update
March 3 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Pôle Vision du val d'Ouest
Écully, France
2
Fondation Adolphe de Rothschild
Paris, France, 75019
3
Hôpital Lariboisière
Paris, France
4
Centre ophtalmologique Maison Rouge
Strasbourg, France